₨ 125,000.00
MBBS
Actemra Infusion 400 mg/20 mL 1 Vialx20 mL
- Does this requires a prescription ? Yes
- Generic Name: Tocilizumab
- Manufactured by : Roche
- Drug Strength : 400 mg/20 mL
- Drug Form : Infusion
- Pack Size : 1 Vialx20 mL
- Product SKU : pg_258_323
Actemra contains Tocilizumab and is now available in Pakistan. The price of Actemra is Rs.125000 as of 1st January 2025 it can be purchased online from MedicalStore.com.pk. The prices are updated regularly on this page.
Alternate brands of Actemra Infusion 400 mg/20 mL 1 Vialx20 mL
| Brand Name | Price | Savings |
|---|---|---|
| Actemra Infusion 200 mg/10 mL 1 Vialx10 mL | ₨ 85,000.00 | You can save 40000 |
| Actemra Infusion SC 162 mg/0.9 mL 4 Vial | ₨ 76,849.00 | You can save 48151 |
| Actemra Infusion 80 mg/4 mL 1 Vialx4 mL | ₨ 11,952.00 | You can save 113048 |
How it works
Actemra Infusion 400 mg/20 mL 1 Vialx20 mL works by reducing the effect of certain specific substances in the body that cause inflammation (pain, redness, swelling, stiffness, etc.) in arthritic conditions.
Side effects
Major & minor side effects for Actemra Infusion 400 mg/20 mL 1 Vialx20 mL
- Mild fever and chills
- High blood pressure
- Skin rash and itching
- Headache
- Flu like symptoms severe
- Sore throat
- Nausea and Vomiting
- Stomach pain
- Constipation
- Mouth blisters
- Joint pain severe
- Difficult and painful breathing severe
- Severe light-headedness severe
- Severe skin rash and hives severe
- Black or tarry stools severe
- Bloody or coffee colored vomit severe
- Blurred vision severe
- Bloody or cloudy urine severe
- Change in heart rate severe
- Unusual bleeding or bruising severe
- Loss of appetite
- Injection site bruising and red coloration
- Loss of consciousness severe
- Skin blistering
- Diarrhea
Uses of Actemra Infusion 400 mg/20 mL 1 Vialx20 mL
What is it prescribed for?
-
Rheumatoid Arthritis
This medicine is indicated for the treatment of rheumatoid arthritis, an immune disorder characterized by pain and swelling of joints. It is normally used when other disease-modifying anti-rheumatoid medications are not effective.
-
Giant cell arteritis
This medicine is indicated for the treatment of giant cell arteritis, a condition where blood vessels, particularly in the head and scalp area, become swollen.
-
Polyarticular juvenile idiopathic arthritis
This medicine is indicated for the treatment of polyarticular juvenile idiopathic arthritis, an arthritic condition in children characterized by swollen and painful joints. It should only be used in children aged 2 years or above.
-
Systemic juvenile idiopathic arthritis
This medicine is indicated for the treatment of systemic juvenile idiopathic arthritis, an inflammatory condition causing fever, pain, swelling, and developmental abnormalities of different parts of the body in children aged 2 years and above.
-
Cytokine release syndrome
This medicine is used for the treatment of cytokine release syndrome, a severe and life-threatening reaction that usually develops after receiving certain immunotherapy medications via infusion.
Concerns
Frequently asked questions
-
Onset of action
The amount of time required for this medicine to show its action is not clinically established.
-
Duration of Effect
The amount of time for which this medicine remains active in the body is not clinically established.
-
Safe with Alchohol?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
-
Is it habit forming?
No habit-forming tendencies were reported.
-
Usage in pregnancy?
This medicine is not recommended for use in pregnant women unless absolutely necessary. All the potential benefits and risks associated with use should be carefully evaluated. Your doctor may prescribe an alternative medicine based on your clinical condition.
-
Usage while breast-feeding?
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before using/receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.
When not to use?
-
Allergy
This medicine is not recommended for use in patients with a known allergy to Actemra Infusion 400 mg/20 mL 1 Vialx20 mL or any other inactive ingredients present along in the formulation. It is also not recommended for use if you have a history of allergy to any other recombinant human or humanized antibodies or proteins that are of hamster origin.
-
Active severe infection
This medicine is not recommended for use in patients suffering from an active severe infection due to the increased risk of worsening of the patient's condition.
-
Low blood cell counts
This medicine is not recommended for use in patients with lower values of absolute neutrophil count and platelet counts. Monitoring of these levels is necessary every 4-8 weeks while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
-
Elevated liver enzymes
This medicine is not recommended for use in patients with ALT and AST levels more than 1.5 times of the upper limit of normal. Monitoring of these levels is necessary every 4-8 weeks while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
-
Lipid abnormalities
This medicine is not recommended for use in patients with higher levels of triglycerides or cholesterol. Monitoring of these levels is necessary every 4-8 weeks while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
-
Immune suppression
Usage of this medicine weakens your immune system, thereby increasing the chances of opportunistic infections. Suitable preventive measures should be adopted to avoid such infections.Usage of this medicine weakens your immune system, thereby increasing the chances of opportunistic infections. Suitable preventive measures should be adopted to avoid such infections.
-
Vaccinations
Vaccinations with live or attenuated strains of micro-organisms should be avoided while taking this medicine due to the increased risk of worsening of the patient’s condition. Similarly, treatment with this medicine should not be initiated if the patient has been vaccinated recently.
-
Other medicines
Actemra 80 mg Injection may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.
-
Heart diseases
This medicine should be used with caution in patients who are suffering from heart diseases due to the increased risk of worsening of the patient's condition. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition of the patient.
-
Driving or operating machinery
Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.
-
Intravenous administration
When used intravenously, this medicine should be infused over a duration of at least 60 minutes.
Dosage
-
Missed Dose
Infusion: Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. Subcutaneous injection: Administer the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.
-
Overdose
Infusion: Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected. Subcutaneous injection: Seek emergency medical treatment or contact the doctor in case of an overdose.
Interactions
Interaction with Medicines- Live vaccines severe
- Adalimumab severe
- Amlodipine moderate
- Phenytoin moderate
- Theophylline moderate
- Cyclosporine moderate
- Warfarin moderate
- Atorvastatin severe
-
severe
This medicine should be used with extreme caution in patients with a history of recent infections and it is not recommended for use in case of active infections due to the increased risk of worsening of the patient’s condition. An alternative treatment option may be necessary in some cases based on the clinical condition of the patient.
-
severe
This medicine is not recommended for use in patients with demyelinating disorders such as chronic inflammatory demyelinating polyneuropathy or multiple sclerosis due to the increased risk of worsening of the patient’s condition. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment may be necessary in some cases based on the clinical condition of the patient.
-
severe
This medicine should be used with caution in patients with gastrointestinal perforations due to the increased risk of worsening of the patient’s condition. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition of the patient.
-
moderate
This medicine should be used with caution in patients with liver diseases. Close monitoring of liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
-
moderate
This medicine should be used with caution in patients with kidney diseases. Close monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
General Instructions
Infusion: This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine. Subcutaneous injection: Follow all the instructions given by your doctor and administer this medicine exactly as advised. Do not administer in larger or smaller amounts than prescribed. Seek emergency medical treatment in case of any severe side effects. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor.
Other details
- Usage does not depend on food timings
- To be taken as instructed by doctor
- May cause sleepiness
References
- practo - Tocilizumab [Internet]. Available from: https://www.practo.com/medicine-info/tocilizumab-1799-api [cited 12/19/2020]. 2018
How to use Actemra Infusion 400 mg/20 mL 1 Vialx20 mL
Dilute to 100 mL and give by IV infusion over 1 hour. For children, dilute to 100 mL (50 mL if lt;30 kg) and given by IV infusion over 1 hour.
Stability: Refrigerate at 2°C-8°C (36°F-46°F). Do not freeze. Protect the vials from light by storage in the original package until time of use. The fully diluted solutions may be stored at 2°C-8°C or room temperature for up to 24 hours and should be protected from light. Unused product remaining in the vials should not be used.
what are the adverse effects of Actemra Infusion 400 mg/20 mL 1 Vialx20 mL?
Infections, headache, hypertension, raised liver enzymes and bilirubin, weight gain, GI upset, mouth ulceration, rash, pruritus, urticaria, dizziness, blood dyscrasias, hypercholesterolaemia, peripheral oedema, cough, dyspnoea.
What happens if I miss a dose of Actemra Infusion 400 mg/20 mL 1 Vialx20 mL?
Adults: Rheumatoid arthritis: By IV infusion initially 4 mg/kg, may be increased to 8 mg/kg (max 800 mg) once every 4 wk.
Children: Active systemic juvenile idiopathic arthritis, in combination with methotrexate or alone if methotrexate inappropriate) who have had an inadequate response to NSAIDs and systemic corticosteroids: IV infusion: 2-18 yr body-weight less than 30 kg, 12 mg/kg once every 2 wk; review treatment if no improvement within 6 wk; body-weight over 30 kg, 8 mg/kg once every 2 wk; review treatment if no improvement within 6 wk.
Polyarticular juvenile idiopathic arthritis, in combination with methotrexate or alone if methotrexate inappropriate who have had an inadequate response to methotrexate: IV infusion: 2-18 yr body-weight less than 30 kg, 10 mg/kg once every 4 wk; review treatment if no improvement within 12 wk; body-weight over 30 kg, 8 mg/kg once every 4 wk; review treatment if no improvement within 12 wk.
One of the following licensed pharmacy from the nearest location will deliver Actemra Infusion 400 mg/20 mL 1 Vialx20 mL. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.
Questions and Answers
There are no questions yet. Be the first to ask a question about this product.
1 review for Actemra Infusion 400 mg/20 mL 1 Vialx20 mL
sadaf mughal –
sadaf mughal submitted 5 stars.